Notes
Costs included wholesale acquisition cost of drug therapy and total hospitalisation costs.
incremental cost-effectiveness ratio
Reference
Stranges PM, et al. Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States. Value in Health 16: 297-304, No. 2, Mar 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2012.11.004
Rights and permissions
About this article
Cite this article
Novel fidaxomicin cost effective for Clostridium difficile infections?. PharmacoEcon Outcomes News 676, 8 (2013). https://doi.org/10.1007/s40274-013-0327-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0327-4